According to MD Anderson administration, Eugenie Kleinerman “decided to step down as Head, Division of Pediatrics, and Chair, Department of Pediatrics, effective Feb. 9 in order to pursue her interests in new initiatives in adolescent and young adult cancer.”
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
